UNSPSC 51322702: Lovastatin

This classification denotes a naphthalene compound and hmg-coa reductase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9LHU78OQFD. European Medicines Agency schedules Lovastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08604MIG. Lovastatin generally arises in the molecular formula C24H36O5.

The term LOVASTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, no. 4, 1987, list 27.) LOVASTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, LOVASTATIN remains the US FDA Preferred Term for this commodity. Lovastatin bears US NLM identifiers UMLS ID C0024027 and NCI Concept Code C620. SMILES: O(C1C2C(C(C=CC2=CC(C1)C)C)CCC1OC(=O)CC(O)C1)C(=O)C(CC)C.

UNSPSC 51322702 Lovastatin, a Commodity code, represents a narrow pharmaceutical line item within state and local emergency medical services, public health, and cooperative purchasing procurement. Recent opportunities show state and local governments soliciting lovastatin and related cardiovascular medications primarily through emergency response procurement (Tampa Fire Rescue advanced life support medications) and multi-state cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance generic pharmaceutical contracts serving state and local facilities across participating jurisdictions). The work involves supply, inventory management, expiration-date compliance, and logistics coordination with authorized wholesalers or direct delivery to end-user agencies. Issuing bodies span municipal fire departments, state health agencies, and cooperative purchasing consortia administering contracts across multiple states and localities. Single-line-item bid solicitations and broad multi-source generic pharmaceutical RFPs both carry the code, creating a mixed procurement environment where lovastatin moves through both direct municipal procurement and aggregated multi-state contracting channels.

Geographic activity centers on Florida and Minnesota-led cooperative purchasing covering Oregon and other member states, with the Texas Health and Human Services Commission conducting preliminary market research into direct-to-manufacturer pharmacy programs that may influence future lovastatin procurement pathways. The City of Tampa issued an IFB (26P00188) due April 8, 2026, for advanced life support medications including related agents, with an estimated contract value of $40,000, a one-year term, and a Small Local Business Enterprise 5 percent bid discount not to exceed $10,000. The Minnesota Multistate Cooperative Purchasing Alliance posted an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products with a two-year contract term effective July 1, 2026, requiring vendors to maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and submit pricing through ePro in CSV format with cGMP and Drug Supply Chain Security Act compliance certification. Texas HHS issued an RFI (HHS0017013) on March 27, 2026, exploring direct-to-manufacturer contracting models outside traditional PBM and GPO channels, signaling potential structural shifts in state pharmacy procurement architecture that may reshape lovastatin distribution and pricing over the next 12–18 months.